These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17883893)

  • 1. Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
    Macha S; Chen L; Norris SH; Philip E; Mao Y; Silverstein H; Struble C; Beers W
    J Pharm Pharmacol; 2007 Sep; 59(9):1223-33. PubMed ID: 17883893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
    MacGregor TR; Sabo JP; Norris SH; Johnson P; Galitz L; McCallister S
    HIV Clin Trials; 2004; 5(6):371-82. PubMed ID: 15682350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
    Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
    Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.
    McCallister S; Valdez H; Curry K; MacGregor T; Borin M; Freimuth W; Wang Y; Mayers DL
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):376-82. PubMed ID: 15097154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
    Langmann P; Winzer R; Schirmer D; Heinz W; Leyh M; Guhl C; Weissbrich B; Klinker H
    Eur J Med Res; 2008 Oct; 13(10):469-71. PubMed ID: 19008174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
    Lee J; Son J; Rhee SW; Kim DH
    Xenobiotica; 2003 Jul; 33(7):755-65. PubMed ID: 12893524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
    Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
    Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
    Mehandru S; Markowitz M
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1821-8. PubMed ID: 14585057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
    de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
    la Porte CJ; Sabo JP; Béïque L; Cameron DW
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
    Garraffo R; Lavrut T; Ferrando S; Durant J; Rouyrre N; MacGregor TR; Sabo JP; Dellamonica P
    J Clin Pharmacol; 2011 Jul; 51(7):1071-8. PubMed ID: 21209236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The absorption, distribution, metabolism and elimination of bevirimat in rats.
    Bullock P; Larsen D; Press R; Wehrman T; Martin DE
    Biopharm Drug Dispos; 2008 Oct; 29(7):396-405. PubMed ID: 18615840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir: a review of its use in the management of HIV infection.
    Orman JS; Perry CM
    Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.